|
|
Indication
Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS in the full prescribing information).
Important Safety Information
All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in appropriate patients. Not all patients with acute ischemic stroke will be eligible for Activase therapy, including patients with evidence of recent or active bleeding; recent (within 3 months) intracranial or intraspinal surgery, serious head trauma, or previous stroke; uncontrolled high blood pressure; or impaired blood clotting.
Please see accompanying full prescribing information for additional Important Safety Information.
|
|
|
|
For a live thought-leader broadcast discussing treatment eligibility and patient outcomes in acute ischemic stroke.
|
|
Webinar will be airing at 12:00 Noon ET, 12:30 PM CT, and 12:00 Noon PT
|
|
|
•
|
Identify eligible acute ischemic stroke patients for treatment with Activase® (alteplase)
|
|
|
•
|
Present clinical benefits and risks of Activase
|
|
•
|
Participate in a live thought-leader Q&A session
|
Presenter
Mark Alberts, MD
Neurologist
Stroke Program Director
Northwestern Memorial Hospital
Chicago, IL
|
|
Panel members
|
|
|
|
|
|
|
|
|
|
Christopher Fanale, MD
Neurologist
HealthONE—Swedish Medical Center
Englewood, CO
|
|
Deborah Summers,
MSN, APN
Clinical Stroke Program Coordinator
Saint Luke’s Brain and Stroke Institute
Kansas City, MO
|
|
David Ghilarducci MD, FACEP
Emergency Physician
O'Connor Hospital
San Jose, CA
|
|
 |
|
|
|
|
|
|
